Analgesic Solutions will join WCG’s clinical services division, which conducts clinical trials through consulting, innovative tools, data science, technology and specialized training.
“We are delighted to welcome Dr. Nathaniel Katz, the founder and chief scientist of Analgesic Solutions, and his extraordinary team of clinicians and scientists to WCG,” Donald A. Deieso, executive chairman and CEO of WCG, said. “The intense public focus on developing alternatives to opioids for use in pain management, as well the organization’s deep understanding of patients’ subjective responses to pain, has made Analgesic Solutions one of the most sought-after solution providers in clinical research.”
Analgesic Solutions will operate independently and retain its headquarters in Wayland, Massachusetts, WCG said. It will also be given access to capital, expertise and operational support from WCG.
“We are very pleased to join WCG – an organization which shares our values, our purpose, and above all, our commitment to scientific integrity,” Katz said. “What excites us most about collaborating with our colleagues at WCG is helping biopharmaceutical sponsors to accelerate the development of pain-reducing therapies by improving the quality of clinical research in this area.”
Financial terms were not disclosed.